Monrovia-based Xencor, a developer of biotherapeutics technology to improve antibodies, said this morning that it has licensed its Fc engineering technology to Centocor Research & Development, Inc. Financial details of the license were not announced. The firm said that it has licensed its XmAb and Xtend technology to Centocor, in a multi-year agreement. Xencor said that the deal will give Centocor research access to the technology platforms, and the right to develop and commercialize products from the technology, in exchange for license fees, milestone payments, and royalties on products commercialized from the collaboration.
Top NewsMonday, November 30, 2009
Xencor Licenses Technology To Centocor